Table 1 Baseline characteristics of study participants

Age

67.7 ± 7.6

Age ≥ 65 (n, %)

350 (65.2)

Male (n, %)

373 (69.5)

Body mass index

24.7 ± 2.9

Past medical history

 Diabetes (n, %)

93 (17.3)

 Hypertension (n, %)

341 (63.5)

 Hyperlipidemia (n, %)

102 (19.0)

 Congestive heart failure (n, %)

31 (5.8)

 Stroke (n, %)

0 (0.0)

 Vascular disease (n, %)

8 (1.5)

CHA₂DS₂-VASc score

2.00 [1.00;3.00]

 0

68 (12.7)

 1

112 (20.9)

 2

166 (30.9)

 3

130 (24.2)

 4

51 (9.5)

 5

10 (1.9)

Number of significant biomarkers*

 0

292 (54.8)

 1

198 (37.1)

 2

38 (7.1)

 3

5 (0.9)

Mean follow-up duration (years)

2.2 ± 0.6

Clinical event during follow-up

Ischemic stroke

10 (1.9)

 CHA₂DS₂-VASc score

  0^†

0 (0.0)

  1^†

1 (0.9)

  2^†

4 (2.4)

  3^†

4 (3.1)

  4^†

1 (2.0)

  5^†

0 (0.0)

Other thromboembolic events

0 (0.0)

 Major bleeding

10 (1.9)

  Hemorrhagic stroke

6 (1.1)

  Gastrointestinal bleeding

5 (0.9)

 Major cardiac adverse event

7 (1.3)

  Myocardial infarction

1 (0.2)

  Heart failure at admission

6 (1.1)

  Cardiac death

0 (0.0)

 Anti-coagulation at baseline (n, %)

382 (71.1)

  Warfarin use

160 (29.8)

  NOAC use

222 (41.3)